Amgen exits neuroscience R&D as pharma pulls back from field
Amgen is stopping its neuroscience research – with the exception of programs centered on neuro-inflammation – as the company concluded that their efforts were unlikely to yield long-term success. As a result, approximately 180 roles will be affected. Amgen will instead prioritize cardiovascular disease, oncology, and inflammatory diseases.
Over the past several years, many industry leaders have exited or pared down their work on neurological diseases, including Pfizer, Bristol-Myers Squibb, GlaxoSmithKline, and AstraZeneca, as successful results have remained elusive.